vimarsana.com
Home
Live Updates
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates : vimarsana.com
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on...
Related Keywords
Boston
,
Massachusetts
,
United States
,
New York
,
San Diego
,
California
,
American
,
Kimberly Blackwell
,
Mark Lackner
,
Program Updates
,
Exchange Commission
,
Nasdaq
,
Zentalis Pharmaceuticals Inc
,
Translational Sciences
,
Genentech
,
Globenewswire Inc
,
Pfizer
,
Genentech Oncology Early Stage Biomarker Group
,
Blackwell
,
Development Expenses
,
Linkedin
,
Pharmaceuticals Inc
,
American Association For Cancer Research
,
Zentalis Pharmaceuticals
,
Translational Officer
,
Chief Scientific Officer
,
Chief Executive Officer
,
Chief Translational Officer
,
New Drug Application
,
Cancer Research
,
Special Conference
,
Staining Is Frequent
,
Prior Platinum Treatment
,
High Grade Serous Ovarian
,
Ovarian Cancer
,
Biomarker Strategy
,
Senior Vice President
,
Oncology Early Stage Biomarker
,
Marketable Securities Position
,
Administrative Expenses
,
Securities Litigation Reform Act
,
Consolidated Statements
,
Markets
,
vimarsana.com © 2020. All Rights Reserved.